Literature DB >> 12640619

Evidence for novel fate of Flk1+ progenitor: contribution to muscle lineage.

Toshiyuki Motoike1, David W Markham, Janet Rossant, Thomas N Sato.   

Abstract

Flk1 is one of the specific cell surface receptors for vascular endothelial growth factor and one of the most specific markers highlighting the earliest stage of hematopoietic and vascular lineages. However, recent new evidence suggests that these Flk1(+) mesodermal progenitor cells also contribute to muscle lineages. All evidence is based on the experiments using in vitro differentiation and in vivo transplantation systems. Although this approach revealed a differentiation potential range of Flk1(+) cells that is wider than previously expected, it fails to determine whether Flk1(+) cells contribute to muscle lineage as part of the normal developmental process. To obtain direct evidence for the fate of Flk1(+) cells in development, we used a knock-in mouse line where Cre is expressed in Flk1(+) cells. Studies with these Cre lines provide direct evidence that Flk1(+) cells are progenitors for muscles, in addition to hematopoietic and vascular endothelial cells. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640619     DOI: 10.1002/gene.10175

Source DB:  PubMed          Journal:  Genesis        ISSN: 1526-954X            Impact factor:   2.487


  89 in total

1.  Systematic engineering of 3D pluripotent stem cell niches to guide blood development.

Authors:  Kelly A Purpura; Andrés M Bratt-Leal; Katy A Hammersmith; Todd C McDevitt; Peter W Zandstra
Journal:  Biomaterials       Date:  2011-11-12       Impact factor: 12.479

2.  Molecular basis for Flk1 expression in hemato-cardiovascular progenitors in the mouse.

Authors:  Hiroyuki Ishitobi; Asami Wakamatsu; Fang Liu; Takuya Azami; Michito Hamada; Ken Matsumoto; Hiroshi Kataoka; Makoto Kobayashi; Kyunghee Choi; Shin-ichi Nishikawa; Satoru Takahashi; Masatsugu Ema
Journal:  Development       Date:  2011-11-09       Impact factor: 6.868

3.  ER71 specifies Flk-1+ hemangiogenic mesoderm by inhibiting cardiac mesoderm and Wnt signaling.

Authors:  Fang Liu; Inyoung Kang; Changwon Park; Li-Wei Chang; Wei Wang; Dongjun Lee; Dae-Sik Lim; Daniel Vittet; Jeanne M Nerbonne; Kyunghee Choi
Journal:  Blood       Date:  2012-02-17       Impact factor: 22.113

Review 4.  Hemogenic endothelium during development and beyond.

Authors:  Karen K Hirschi
Journal:  Blood       Date:  2012-03-13       Impact factor: 22.113

5.  ER71 directs mesodermal fate decisions during embryogenesis.

Authors:  Tara L Rasmussen; Junghun Kweon; Mackenzie A Diekmann; Fikru Belema-Bedada; Qingfeng Song; Kathy Bowlin; Xiaozhong Shi; Anwarul Ferdous; Tongbin Li; Michael Kyba; Joseph M Metzger; Naoko Koyano-Nakagawa; Daniel J Garry
Journal:  Development       Date:  2011-11       Impact factor: 6.868

Review 6.  Myeloid cells and lymphangiogenesis.

Authors:  Adrian Zumsteg; Gerhard Christofori
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

7.  Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors.

Authors:  Catherine J Drummond; Jason A Hanna; Matthew R Garcia; Daniel J Devine; Alana J Heyrana; David Finkelstein; Jerold E Rehg; Mark E Hatley
Journal:  Cancer Cell       Date:  2018-01-08       Impact factor: 31.743

Review 8.  Developmental relationship between hematopoietic and endothelial cells.

Authors:  Jesse J Lugus; Changwon Park; Kyunghee Choi
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

9.  Sox17 is essential for the specification of cardiac mesoderm in embryonic stem cells.

Authors:  Yu Liu; Masanori Asakura; Hironori Inoue; Teruya Nakamura; Motoaki Sano; Zhiyv Niu; Michelle Chen; Robert J Schwartz; Michael D Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-28       Impact factor: 11.205

10.  Both primitive and definitive blood cells are derived from Flk-1+ mesoderm.

Authors:  Jesse J Lugus; Changwon Park; Yunglin D Ma; Kyunghee Choi
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.